The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Antonino Capizzi, Michela Silvestri, Andrea Orsi, Renato Cutrera, Giovanni A Rossi, Oliviero Sacco

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the = 29 wGA subpopulation when specific risk factors are present.
Original languageEnglish
JournalItalian Journal of Pediatrics
Volume43
Issue number1
DOIs
Publication statusPublished - Aug 14 2017

Fingerprint

Bronchiolitis
National Health Programs
Prescriptions
Epidemiology
Pediatrics
Incidence
Pharmaceutical Preparations
Palivizumab
antiarrhythmic peptide

Keywords

  • Letter

Cite this

@article{625a3fca017a40028f45460caa53d711,
title = "The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence",
abstract = "Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the = 29 wGA subpopulation when specific risk factors are present.",
keywords = "Letter",
author = "Antonino Capizzi and Michela Silvestri and Andrea Orsi and Renato Cutrera and Rossi, {Giovanni A} and Oliviero Sacco",
year = "2017",
month = "8",
day = "14",
doi = "10.1186/s13052-017-0390-8",
language = "English",
volume = "43",
journal = "Italian Journal of Pediatrics",
issn = "1720-8424",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

AU - Capizzi, Antonino

AU - Silvestri, Michela

AU - Orsi, Andrea

AU - Cutrera, Renato

AU - Rossi, Giovanni A

AU - Sacco, Oliviero

PY - 2017/8/14

Y1 - 2017/8/14

N2 - Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the = 29 wGA subpopulation when specific risk factors are present.

AB - Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the = 29 wGA subpopulation when specific risk factors are present.

KW - Letter

U2 - 10.1186/s13052-017-0390-8

DO - 10.1186/s13052-017-0390-8

M3 - Article

VL - 43

JO - Italian Journal of Pediatrics

JF - Italian Journal of Pediatrics

SN - 1720-8424

IS - 1

ER -